21st International AIDS Conference (AIDS 2016)


Paul Stoffels: A Career Spent Developing HIV Medications and Vaccines

July 31, 2016

On behalf of IFARA, Fred Schaich spoke with Paul Stoffels, M.D., at this year's International AIDS Conference about his career and a current HIV vaccine trial. As a medical student, Stoffels worked in African hospitals and saw his first HIV patient in 1983. At that time almost everyone infected died because little treatment was available. A doctor can only impact the health of one person at a time and can only do so if the appropriate tools, such as medications, are available, Stoffels said. He met drug researcher Paul Janssen in 1990 and moved into medication research as a way to have a greater impact on HIV. The first antiretrovirals developed by Janssen's team failed because HIV very quickly became resistant to them. This experience led to the development of combination antiretroviral therapy.

Because of better medications, both for initial treatment and second-line therapy, life expectancy for people living with HIV is now normal. That, however, means that people have to take medications for 50 years or so. "That's not a solution," Stoffels believes. His company, Johnson & Johnson, is now studying three different prime-boost HIV vaccines in a clinical trial of 400 participants who will receive four injections over the course of a year. The objective is to achieve better than 50% protection from acquiring the virus. If that goal is met, a phase IIb study of that prevention method may start sometime next year.

Watch the video to learn more:

About the panelist:

  • Paul Stoffels, M.D., Johnson & Johnson

The video above has been posted on with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the conference, as well as earlier meetings.

Barbara Jungwirth is a freelance writer and translator based in New York.

Follow Barbara on Twitter: @reliabletran.

Copyright © 2016 Remedy Health Media, LLC. All rights reserved.

Related Stories

The Current State of HIV Cure Research: An Interview With Carl Dieffenbach
NIH's Dr. Dieffenbach Shares Updates on HIV Vaccine Research From Second Day of AIDS 2016
Next Up -- Country-Specific HIV Vaccines

This article was provided by TheBodyPRO. It is a part of the publication The 21st International AIDS Conference (AIDS 2016).

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.